Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The evidence for the use of antipsychotic medication in the treatment of early-onset schizophrenia (onset at age less than 18 years), based on an increasing number of randomized controlled trials, points to therapeutic efficacy with moderate-to-large effect sizes. Some of the trials, however, were of short duration and a few were industry funded. Medication with both first-generation (FGA) and second-generation (SGA) antipsychotics is also associated with considerable side effects. Nevertheless, cautious use alongside psychosocial interventions can be recommended, provided there is continued, careful monitoring. © 2008 Elsevier Ltd. All rights reserved.

Original publication

DOI

10.1016/j.mppsy.2008.08.002

Type

Journal article

Journal

Psychiatry

Publication Date

01/11/2008

Volume

7

Pages

458 - 462